The Journal of Allergy and Clinical Immunology
Volume 107, Issue 2 , Pages 203-210 , February 2001

Health economics of asthma and rhinitis. II. Assessing the value of interventions

Received 7 November 2000 ,Accepted 10 November 2000.

References 

  1. In:  Sackett DL,  Richardson WS,  Rosenberg W,  Haynes RB editor. Evidence-based medicine: how to practice and teach EBM. New York: : Churchill Livingstone; 1997;
  2. Counsel on Ethical and Judicial Affairs, American Medical Association . Ethical issues in managed care. JAMA. 1995;273:330–335
  3. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol. 2000;107:3–8
  4. Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. New York: : Oxford University Press; 1997;
  5. In:  Gold MR,  Siegel JE,  Russell LB,  Weinstein MC editor. Cost-effectiveness in health and medicine. New York: : Oxford University Press; 1996;
  6. In:  Haddix AC,  Teutsch SM,  Shaffer PA,  Dunet DO editor. Prevention effectiveness: a guide to decision analysis and economic evaluation. New York: : Oxford University Press; 1996;
  7. Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. New York: : Oxford University Press; 1987;
  8. Banta HD, Luce BR. Health care technology and its assessment. New York: : Oxford University Press; 1993;
  9. Warner KE, Luce BR. Cost-benefit and cost-effectiveness analysis in health care: principles, practice, and potential. Ann Arbor (MI): : Health Administration Press; 1982;
  10. Garber AM, Weinstein MC, Torrance GW, Kamlet MS. Theoretical foundations of cost-effectiveness analysis. In:  Gold MR,  Siegel JE,  Russell LB,  Weinstein MC editor. Cost-effectiveness in health and medicine. New York: : Oxford University Press; 1996;p. 25–53
  11. Sullivan S, Elixhauser A, Buist AS, Luce BR, Eisenberg J, Weiss KB. National Asthma Education and Prevention Program working group report on the cost-effectiveness of asthma care. Am J Respir Crit Care Med. 1996;154:S85–S95
  12. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma. Bethesda (MD): : National Institutes of Health; April 1997; Publication No. 97-4051
  13. van den Boom G, van Schayck CP, van Mollen MP, Tirimanna PR, den Otter JJ, van Grunsven PM, et al.  Active detection of chronic obstructive pulmonary disease and asthma in the general population. Am J Respir Crit Care Med. 1998;158:1730–1738
  14. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:177–183
  15. O’Reilly JF, Weir DC, Banham S, Basran GS, Boyd G, Patel KR. Is high-dose fluticasone propionate via a metered-dose inhaler and Volumatic as efficacious as nebulized budesonide in adult asthmatics?. Respir Med. 1998;92:111–117
  16. Lord J, Ducharme FM, Stamp RJ, Littlejohns P, Churchill R. Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma. BMJ. 1999;319:1470–1471
  17. Booth PC, Wells NE, Morrison AK. A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma. Pharmacoeconomics. 1996;10:262–268
  18. Campbell LM, Simpson RJ, Turbitt ML, et al.  A comparison of the cost-effectiveness of budesonide 400 μg/day and 800 μg/day in the management of mild-to-moderate asthma in general practice. Br J Med Econ. 1993;6:67–74
  19. Sculpher MJ, Buxton MJ. Episode-free days as endpoints in economic evaluations of asthma therapy. Pharmacoeconomics. 1993;4:345–352
  20. Johansson G, Price MJ, Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100 microgram versus fluticasone propionate 100 microgram in adults and adolescents with asthma. III: Results. Pharmacoeconomics. 1999;16:15–21
  21. Palmqvist M, Price MJ, Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250 microgram versus fluticasone propionate 250 micrograms versus fluticasone propionate 250 micrograms in adults and adolescents with asthma. IV: Results. Pharmacoeconomics. 1999;16:23–28
  22. Pieters WR, Lundback B, Sondhi S, Price MJ, Thwaites RM. Cost-effectiveness analysis of salmeterol/fluticasone 50/500 micrograms versus fluticasone propionate 500 micrograms in patients with corticosteroid-dependent asthma. V: Results. Pharmacoeconomics. 1999;16:29–34
  23. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis. 1993;148:S1–S26
  24. The Childhood Asthma Management Program Research Group . Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054–1063
  25. Gerdtham UG, Hertzman P, Jonsson B, Boman G. Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden 1978-1991. Med Care. 1996;34:1188–1198
  26. Price DB, Appleby JL. Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care. Respir Med. 1998;92:351–353
  27. Balkrishnan R, Norwood GJ, Anderson A. Outcomes and cost-benefits associated with the introduction of inhaled corticosteroid therapy in a Medicaid population of asthmatic patients. Clin Ther. 1998;20:567–580
  28. Adelroth E, Thompson S. Advantages of high-dose inhaled budesonide. Lancet. 1988;1:476
  29. Perera BJ. Efficacy and cost effectiveness of inhaled steroids in asthma in a developing country. Arch Dis Child. 1995;72:312–316
  30. Holzer SS, Engelhart L, Crown WH, L’Herrou TA, Kennedy ST. Asthma treatment costs using inhaled corticosteroids. Am J Managed Care. 1997;3:891–897
  31. Barton S. Which clinical studies provide the best evidence? The best RCT still trumps the best observational study. BMJ. 2000;321:255–256
  32. Popcock SJ, Elbourne DR. Randomized trials of observational tribulations?. N Engl J Med. 2000;342:1907–1909
  33. O’Byrne P, Cuddy L, Taylor DW, Birch S, Morris J, Syrotuik J. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care. Can Respir J. 1996;3:169–175
  34. Connett GJ, Lenney W, McConchie SM. The cost-effectiveness of budesonide in severe asthmatics aged one to three years. Br J Med Econ. 1993;6:127–134
  35. Rutten-van Mölken MP, Van Doorslaer EK, Jansen MC, Van Essen-Zandvliet EE, Rutten FF. Cost-effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. Pharmacoeconomics. 1993;4:257–270
  36. Rutten-van Mölken MP, Van Doorslaer EK, Jansen MC, Kerstjens HA, Rutten FF. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151:975–982
  37. Barnes NC, Thwaites RM, Price MJ. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respir Med. 1999;93:402–407
  38. Rutten-van Mölken MP, van Doorslaer EK, Till MD. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. Pharmacoeconomics. 1998;14:671–684
  39. Lundback B, Jenkins C, Price MJ, Thwaites MA. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micrograms twice daily and budesonide 800 micrograms twice daily in the treatment of adults and adolescents with asthma. Respir Med. 2000;94:724–732
  40. Ross RN, Morris M, Sakowitz SR, Berman BA. Cost-effectiveness of including cromolyn sodium in the treatment program for asthma: a retrospective, record-based study. Clin Ther. 1988;10:188–203
  41. Thomas P, Ross RN, Farrar JR. A retrospective assessment of cost avoidance associated with the use of nedocromil sodium metered-dose inhaler in the treatment of patients with asthma. Clin Ther. 1996;18:939–952
  42. Lord J, Ducharme FM, Stamp RJ, Littlejohns P, Churchill R. Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma. BMJ. 1999;319:1470–1471
  43. Thomas K, Peter JV, Cherian AM, Guyatt G. Cost-effectiveness of inhaled beta-agonists versus oral salbutamol in asthma: a randomized double blind cross over study. Natl Med J India. 1996;9:159–162
  44. Camargo CA, Kenny PA. Assessing costs of aerosol therapy. Respir Care. 2000;45:756–763
  45. Jasper AN, Mohsenifar Z, Kahan S, Goldberg HS, Koerner SK. Costbenefit comparison of aerosol bronchodilator delivery methods in hospitalized patients. Chest. 1987;91:614–618
  46. Summer W, Elston R, Tharpe L, Nelson S, Haponik EF. Aerosol bronchodilator delivery methods. Relative impact on pulmonary function and cost of respiratory care. Arch Intern Med. 1989;149:618–623
  47. Bowton DL, Goldsmith WM, Haponik EF. Substitution of metered-dose inhalers for hand-held nebulizers: success and cost savings in a large, acute-care hospital. Chest. 1992;101:305–308
  48. Orens DK, Kester L, Fergus LC, Stoller JK. Cost impact of metered dose inhalers vs small volume nebulizers in hospitalized patients: the Cleveland Clinic experience. Respir Care. 1991;36:1099–1114
  49. Turner MO, Gafni A, Swan D, Fitzgerald JM. A review and economic evaluation of bronchodilator delivery methods in hospitalized patients. Arch Intern Med. 1996;156:2113–2118
  50. Cates CJ. Holding chambers versus nebulizers for beta agonist treatment of acute asthma. (Cochrane Review) Issue 3. In: The Cochrane Library  editors. Oxford: Update Software; 1999;
  51. Kelloway JS, Wyatt R. A cost-effectiveness analysis of breath-actuated metered-dose inhalers. Managed Care Interface. 1997;10:99–107
  52. Langley PC. The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalers. Clin Ther. 1999;21:236–253
  53. Liljas B, Stadhl E, Pauwels RA. Cost-effectiveness analysis of a dry powder inhaler (Turbuhaler) versus a pressurized metered dose inhaler in patients with asthma. Pharmacoeconomics. 1997;12:267–277
  54. Green L. Toward cost-benefit evaluations of health education: some concepts, methods and examples. Health Educ Monogr. 1974;2:34–64
  55. Boulet L, Champan K, Green L, FitzGerald J. Asthma education. Chest. 1994;106:184S-96S
  56. Windsor RA, Bailey WC, Richards JM, Manzella B, Soong SJ, Brooks M. Evaluation of the efficacy and cost effectiveness of health education methods to increase medication adherence among adults with asthma. Am J Public Health. 1990;80:1519–1521
  57. Muhlhauser I, Richter B, Kraut D, Weske G, Worth H, Berger M. Evaluation of a structured treatment and teaching programme on asthma. J Intern Med. 1991;238:157–164
  58. Lawrence G. Asthma self-management programs can reduce the need for hospital-based asthma care. Respir Care. 1995;40:39–43
  59. Trautner C, Richter B, Berger M. Cost-effectiveness of a structured treatment and teaching programme on asthma. Eur Respir J. 1993;6:1485–1491
  60. Bolton MB, Tilley BC, Kuder J, Reeves T, Schultz LR. The cost and effectiveness of an education program for adults who have asthma. J Gen Intern Med. 1991;6:401–407
  61. Soondergaard B, Davidsen F, Kirkeby B, Rasmussen M, Hey H. The economics of an intensive education programme for asthmatic patients: a prospective controlled trial. Pharmacoeconomics. 1992;1:207–212
  62. Fireman P, Friday GA, Gira C, Vierthaler WA, Michaels L. Teaching self-management skills to asthmatic children and their parents in an ambulatory care setting. Pediatrics. 1981;68:341–348
  63. Lewis CE, Rachelefsky G, Lewis MA, de la Soto A, Kaplan M. A randomized trial of ACT (asthma care training) for kids. Pediatrics. 1984;74:478–486
  64. Clark NM, Feldman CH, Evans D, Levison MJ, Wasilewski Y, Mellins RB. The impact of health education on frequency and cost of health care use by low income children with asthma. J Allergy Clin Immunol. 1986;78:108–115
  65. Neri M, Migliori GB, Spanevello A, Berra D, Nicolin E, Landoni CV, et al.  Economic analysis of two structured treatment and teaching programs on asthma. Allergy. 1996;51:313–319
  66. Lahdensuo A, Haahtela T, Herrala J, Kava T, Kiviranta K, Kuusisto P, et al.  Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland. BMJ. 1998;316:1138–1139
  67. Kauppinen R, Sintonen H, Tukiainen H. One-year economic evaluation of intensive vs conventional patient education and supervision for self-management of new asthmatic patients. Respir Med. 1998;92:300–307
  68. Ghosh CS, Ravindran P, Joshi M, Stearns SC. Reductions in hospital use from self management training for chronic asthmatics. Soc Sci Med. 1998;46:1087–1093
  69. Freund DA, Stein J, Hurley R, Engel W, Woomert A, Lee B. The Kansas City asthma care project: specialty differences in the costs of treating asthma. Ann Allergy. 1988;60:3–7
  70. Westley CR, Spiecher R, Starr L, Simons P, Sanders B, Marsh W, et al.  Cost effectiveness of an allergy consultation in the management of asthma. Allergy Asthma Proc. 1997;18:15–18
  71. Zwicke DL, Donohue JF, Wagner EH. Use of the emergency department observation unit in the treatment of acute asthma. Ann Am Med. 1982;11:77–83
  72. Marks MK, Lovejoy FH, Rutherford PA, Baskin MN. Impact of a short stay unit on asthma patients admitted to a tertiary pediatric hospital. Quality Management in Health Care. 1997;6:14–22
  73. Rydman RJ, Isola ML, Roberts RR, Zalenski RJ, McDermott MR, Murphy DG, et al.  Emergency department observation unit versus hospital inpatient care for a chronic asthmatic population. Med Care. 1998;36:599–609
  74. Doan T, Grammer LC, Yarnold PR, Greenberger PA, Patterson R. An intervention program to reduce the hospitalization cost of asthma patients requiring intubation. Ann Allergy Asthma Immunol. 1996;76:513–518
  75. McDowell KM, Chatburn RL, Myers TR, O’Riordan MA, Kercsmar CM. A cost-saving algorithm for children hospitalized for status asthmaticus. Arch Pediatr Adolesc Med. 1998;152:977–984
  76. Bailey R, Weingarten S, Lewis M, Mohsenifar Z. Impact of clinical pathways and practice guidelines on the management of acute exacerbations of bronchial asthma. Chest. 1998;113:28–33
  77. Kelly SX, Anderson CL, Pestian JP, Wenger AD, Finch AB, Strope GL, et al.  Ann Allergy Asthma Immunol. 2000;84:509–516
  78. Kwan-Gett TS, Lozano P, Mullin K, Marcuse EK. One-year experience with an inpatient asthma clinical pathway. Arch Pediatr Adolesc Med. 1997;151:684–690
  79. Hunter DJ, Fairfield F. Disease management. BMJ. 1997;315:50–53
  80. Harris JM. Disease management: new wine in new bottles?. Ann Intern Med. 1996;124:838–842
  81. Epstein RS, Sherwood LM. From outcomes research to disease management: a guide for the perplexed. Ann Intern Med. 1996;124:832–837
  82. Integrated care for asthma: a clinical, social, and economic evaluation . Grampian Asthma Study of Integrated Care. BMJ. 1994;308:559–564
  83. Kelly CS, Morrow AL, Shults J, Nakas N, Strope GL, Adelman RD. Outcomes evaluation of a comprehensive intervention program for asthmatic children enrolled in Medicaid. Pediatrics. 2000;105:1029–1035
  84. Gilmet GP, Zeitz HJ, Lewandowski JJ. Pediatric asthma outcomes after implementation of a disease management model: the Asthmatter of Fact Program. Disease Management. 2000;3:11–19
  85. Levenson T, Grammer LC, Yarnold PR, Patterson R. Cost-effective management of malignant potentially fatal asthma. Allergy Asthma Proc. 1997;18:73–78
  86. Jowers JR, Schwartz AL, Tinkelman DG, Reed KE, Corsello PR, Mazzei AA, et al.  Disease management program improves asthma outcomes. Am J Managed Care. 2000;6:585–592
  87. Greineder DK, Loane KC, Parks P. A randomized controlled trial of a pediatric asthma outreach program. J Allergy Clin Immunol. 1999;103:436–440
  88. Watanabe T, Ohta M, Murata M, Yamamoto T. Decrease in emergency room or urgent care visits due to management of bronchial asthma inpatients and outpatients with pharmaceutical services. J Clin Pharm Ther. 1998;23:303–309
  89. Curtin K, Hayes BD, Holland CL, Katz LA. Computer-generated intervention for asthma population care management. Effective Clinical Practice. 1998;1:43–46
  90. Rossiter LF, Whitehurse-Cook MY, Small RE, Shasky C, Bovbjerg VE, Penberthy L, et al.  The impact of disease management on outcomes and costs of care: a study of low-income asthma patients. Inquiry. 2000;37:188–202
  91. O’Connor JF, Singer ME, Richter JE. The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma. Am J Gastroenterol. 1999;94:1472–1480
  92. Deter HC. Cost-benefit analysis of psychosomatic therapy in asthma. J Psychosom Res. 1986;30:173–182
  93. Munroe WP, Kunz K, Dalmady-Israel C, Potter L, Schonfeld WH. Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting. Clin Ther. 1997;19:113–123
  94. Knoell DL, Pierson JF, Marsh CB, Allen JN, Pathak DS. Measurement of outcomes in adults receiving pharmaceutical care in a comprehensive asthma outpatient clinic. Pharmacotherapy. 1998;18:1365–1374
  95. McCowen C, Neville RG, Crombie IK, Clark RA, Warner FC. The facilitator effect: results from a four-year follow-up of children with asthma. Br J Gen Pract. 1997;47:156–160
  96. Kozma CM, Schulz RM, Sclar DA, Kral KM, Mackowiak JI. A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis. Clin Ther. 1996;18:334–346
  97. Stahl E, van Rompay W, Yang EC, Thomson DM. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2000;84:397–402
  98. Keith PK, Haddon J, Birch S, for the Rhinocort Study Group . A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal bude-sonide for seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2000;84:55–62
  99. Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics. 2000;17:37–52
  100. Santos R, Cifaldi M, Gregory C, Seitz P. Economic outcomes of a targeted intervention program: the costs of treating allergic rhinitis patients. Am J Managed Care. 1999;5:S225–S234

☆ Supported by a grant from Astra Pharmaceuticals, Westborough, Mass

☆☆ Supported in part by an educational grant from the Asthma and Allergy Foundation of America.

★ Reprint requests: Kevin B. Weiss, MD, Director, Center for Health Services Research, Rush Primary Care Institute, Rush-Presbyterian-St Luke’s Medical Center, 1653 W Congress Pkwy, Chicago, IL 60612.

PII: S0091-6749(01)96050-6

doi: 10.1067/mai.2001.112851

The Journal of Allergy and Clinical Immunology
Volume 107, Issue 2 , Pages 203-210 , February 2001

Article Tools